Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"

Bone Metastases Clinical Trial

— OOSLOH  

Official title:

Regional Database for Collecting Clinical-biological and Imaging Data "Secondary Bone Oncology and Bone Localizations of Hematologic Diseases"

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05495802
• Other study ID #: 2019_59
• Secondary ID: 2021-A00829-32
• Status: Not yet recruiting
• Start date: December 2022
• Est. completion date: December 2032

Study information

• Verified date: August 2022
• Source: University Hospital, Lille
• Contact: Marie-Hélène VIELLARD, MD
• Phone: 0320445962
• Email: Marie-Helene.VIEILLARD[@]chu-lille.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Improving the effectiveness of cancer treatments makes it possible to lengthen patient survival. It is therefore important to ensure that the quality of life is also maintained by reducing pain and handicap.

Some cancers tend to spread to the bone. The bone locations of cancer can weaken the bone and lead to complications such as fractures, pain, or compression of neurological structures.

To avoid such complications, weekly multidisciplinary meetings (MM) bring together specialists (oncologists, rheumatologists, cancer surgeons, radiologists, radiotherapists, etc.) to discuss the files of patients with bone lesions from cancer. They offer specific treatments adapted to each patient to treat or reduce the risk of complications. The OOSLOH study aims to collect clinical, biological, and imaging data from patients for whom a discussion took place in bone dedicated MM. Based on these data, epidemiological studies could be carried out to better understand the clinical factors leading cancer to colonize bone. But also to determine the factors making it possible to prevent or better treat bone complications and improve the quality of life of patients. This study does not require any examinations or additional visits to the patient

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 5000
• Est. completion date: December 2032
• Est. primary completion date: November 2032
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient aged 18 or over,

• Patient whose file is presented to the OOSLOH MM and who has not objected to the use of his non-nominative clinical, biological and imaging data

• Social insured patient

Exclusion Criteria:

• Patient who died before presentation to OOSLOH MM,

• Minor patient,

• Patient objecting to the use of their data for research purposes,

• Patient unable to express his right to object to his participation in the study.

Related Conditions & MeSH terms

• Bone Metastases
• Hematologic Diseases
• Neoplasm Metastasis

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Lille	Lille University Hospital Emergence Fund

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of alive patients		through study completion, an average of 10 years
Secondary	Percentage of patients without bone disease recurrence		within one year after the multidisciplinary meeting
Secondary	Time to bone disease recurrence		through study completion, an average of 10 years
Secondary	Number of bone recurrence Number of bone recurrence		At each presentation of the patient file's to the MM,on average every week
Secondary	Epidemiological datas		At the first presentation of patient's file to the MM, on average every week